CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of infectious diseases
3.4.1.2. Increase in consumption of oral antibiotics
3.4.1.3. Rise in investments in R&D activities
3.4.2. Restraints
3.4.2.1. Development of antibiotic resistance
3.4.2.2. Time consuming approvals
3.4.3. Opportunities
3.4.3.1. Discovery of advanced therapies to treat antibiotic- resistance.
CHAPTER 4: ORAL ANTIBIOTICS MARKET, BY CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Beta Lactam and Beta Lactamase Inhibitors
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Beta Lactam and Beta Lactamase Inhibitors Oral Antibiotics Market by Type
4.2.4.1. Penicillin Oral Antibiotics Market by Spectrum of Activity
4.3. Quinolone
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Macrolide
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY
5.1. Overview
5.1.1. Market size and forecast
5.2. Broad-spectrum Antibiotic
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Mid/Narrow-spectrum antibiotic
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ORAL ANTIBIOTICS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Community-acquired respiratory tract infections (CARTIs)
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.2.4. Community-acquired respiratory tract infections (CARTIs) Oral Antibiotics Market by Type
6.3. Urinary tract infections (UTIs)
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Dental
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN
7.1. Overview
7.1.1. Market size and forecast
7.2. Natural
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Semisynthetic
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Synthetic
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ORAL ANTIBIOTICS MARKET, BY DRUG TYPE
8.1. Overview
8.1.1. Market size and forecast
8.2. Branded
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by region
8.2.3. Market share analysis by country
8.3. Generic
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by region
8.3.3. Market share analysis by country
CHAPTER 9: ORAL ANTIBIOTICS MARKET, BY REGION
9.1. Overview
9.1.1. Market size and forecast By Region
9.2. North America
9.2.1. Key market trends, growth factors and opportunities
9.2.2. Market size and forecast, by Class
9.2.3. Market size and forecast, by Spectrum of Activity
9.2.4. Market size and forecast, by Application
9.2.5. Market size and forecast, by Drug Origin
9.2.6. Market size and forecast, by Drug Type
9.2.7. Market size and forecast, by country
9.2.7.1. U.S.
9.2.7.1.1. Market size and forecast, by Class
9.2.7.1.2. Market size and forecast, by Spectrum of Activity
9.2.7.1.3. Market size and forecast, by Application
9.2.7.1.4. Market size and forecast, by Drug Origin
9.2.7.1.5. Market size and forecast, by Drug Type
9.2.7.2. Canada
9.2.7.2.1. Market size and forecast, by Class
9.2.7.2.2. Market size and forecast, by Spectrum of Activity
9.2.7.2.3. Market size and forecast, by Application
9.2.7.2.4. Market size and forecast, by Drug Origin
9.2.7.2.5. Market size and forecast, by Drug Type
9.2.7.3. Mexico
9.2.7.3.1. Market size and forecast, by Class
9.2.7.3.2. Market size and forecast, by Spectrum of Activity
9.2.7.3.3. Market size and forecast, by Application
9.2.7.3.4. Market size and forecast, by Drug Origin
9.2.7.3.5. Market size and forecast, by Drug Type
9.3. Europe
9.3.1. Key market trends, growth factors and opportunities
9.3.2. Market size and forecast, by Class
9.3.3. Market size and forecast, by Spectrum of Activity
9.3.4. Market size and forecast, by Application
9.3.5. Market size and forecast, by Drug Origin
9.3.6. Market size and forecast, by Drug Type
9.3.7. Market size and forecast, by country
9.3.7.1. Germany
9.3.7.1.1. Market size and forecast, by Class
9.3.7.1.2. Market size and forecast, by Spectrum of Activity
9.3.7.1.3. Market size and forecast, by Application
9.3.7.1.4. Market size and forecast, by Drug Origin
9.3.7.1.5. Market size and forecast, by Drug Type
9.3.7.2. France
9.3.7.2.1. Market size and forecast, by Class
9.3.7.2.2. Market size and forecast, by Spectrum of Activity
9.3.7.2.3. Market size and forecast, by Application
9.3.7.2.4. Market size and forecast, by Drug Origin
9.3.7.2.5. Market size and forecast, by Drug Type
9.3.7.3. UK
9.3.7.3.1. Market size and forecast, by Class
9.3.7.3.2. Market size and forecast, by Spectrum of Activity
9.3.7.3.3. Market size and forecast, by Application
9.3.7.3.4. Market size and forecast, by Drug Origin
9.3.7.3.5. Market size and forecast, by Drug Type
9.3.7.4. Italy
9.3.7.4.1. Market size and forecast, by Class
9.3.7.4.2. Market size and forecast, by Spectrum of Activity
9.3.7.4.3. Market size and forecast, by Application
9.3.7.4.4. Market size and forecast, by Drug Origin
9.3.7.4.5. Market size and forecast, by Drug Type
9.3.7.5. Spain
9.3.7.5.1. Market size and forecast, by Class
9.3.7.5.2. Market size and forecast, by Spectrum of Activity
9.3.7.5.3. Market size and forecast, by Application
9.3.7.5.4. Market size and forecast, by Drug Origin
9.3.7.5.5. Market size and forecast, by Drug Type
9.3.7.6. Rest of Europe
9.3.7.6.1. Market size and forecast, by Class
9.3.7.6.2. Market size and forecast, by Spectrum of Activity
9.3.7.6.3. Market size and forecast, by Application
9.3.7.6.4. Market size and forecast, by Drug Origin
9.3.7.6.5. Market size and forecast, by Drug Type
9.4. Asia-Pacific
9.4.1. Key market trends, growth factors and opportunities
9.4.2. Market size and forecast, by Class
9.4.3. Market size and forecast, by Spectrum of Activity
9.4.4. Market size and forecast, by Application
9.4.5. Market size and forecast, by Drug Origin
9.4.6. Market size and forecast, by Drug Type
9.4.7. Market size and forecast, by country
9.4.7.1. Japan
9.4.7.1.1. Market size and forecast, by Class
9.4.7.1.2. Market size and forecast, by Spectrum of Activity
9.4.7.1.3. Market size and forecast, by Application
9.4.7.1.4. Market size and forecast, by Drug Origin
9.4.7.1.5. Market size and forecast, by Drug Type
9.4.7.2. China
9.4.7.2.1. Market size and forecast, by Class
9.4.7.2.2. Market size and forecast, by Spectrum of Activity
9.4.7.2.3. Market size and forecast, by Application
9.4.7.2.4. Market size and forecast, by Drug Origin
9.4.7.2.5. Market size and forecast, by Drug Type
9.4.7.3. India
9.4.7.3.1. Market size and forecast, by Class
9.4.7.3.2. Market size and forecast, by Spectrum of Activity
9.4.7.3.3. Market size and forecast, by Application
9.4.7.3.4. Market size and forecast, by Drug Origin
9.4.7.3.5. Market size and forecast, by Drug Type
9.4.7.4. Australia
9.4.7.4.1. Market size and forecast, by Class
9.4.7.4.2. Market size and forecast, by Spectrum of Activity
9.4.7.4.3. Market size and forecast, by Application
9.4.7.4.4. Market size and forecast, by Drug Origin
9.4.7.4.5. Market size and forecast, by Drug Type
9.4.7.5. South Korea
9.4.7.5.1. Market size and forecast, by Class
9.4.7.5.2. Market size and forecast, by Spectrum of Activity
9.4.7.5.3. Market size and forecast, by Application
9.4.7.5.4. Market size and forecast, by Drug Origin
9.4.7.5.5. Market size and forecast, by Drug Type
9.4.7.6. Rest of Asia-Pacific
9.4.7.6.1. Market size and forecast, by Class
9.4.7.6.2. Market size and forecast, by Spectrum of Activity
9.4.7.6.3. Market size and forecast, by Application
9.4.7.6.4. Market size and forecast, by Drug Origin
9.4.7.6.5. Market size and forecast, by Drug Type
9.5. LAMEA
9.5.1. Key market trends, growth factors and opportunities
9.5.2. Market size and forecast, by Class
9.5.3. Market size and forecast, by Spectrum of Activity
9.5.4. Market size and forecast, by Application
9.5.5. Market size and forecast, by Drug Origin
9.5.6. Market size and forecast, by Drug Type
9.5.7. Market size and forecast, by country
9.5.7.1. Brazil
9.5.7.1.1. Market size and forecast, by Class
9.5.7.1.2. Market size and forecast, by Spectrum of Activity
9.5.7.1.3. Market size and forecast, by Application
9.5.7.1.4. Market size and forecast, by Drug Origin
9.5.7.1.5. Market size and forecast, by Drug Type
9.5.7.2. Saudi Arabia
9.5.7.2.1. Market size and forecast, by Class
9.5.7.2.2. Market size and forecast, by Spectrum of Activity
9.5.7.2.3. Market size and forecast, by Application
9.5.7.2.4. Market size and forecast, by Drug Origin
9.5.7.2.5. Market size and forecast, by Drug Type
9.5.7.3. South Africa
9.5.7.3.1. Market size and forecast, by Class
9.5.7.3.2. Market size and forecast, by Spectrum of Activity
9.5.7.3.3. Market size and forecast, by Application
9.5.7.3.4. Market size and forecast, by Drug Origin
9.5.7.3.5. Market size and forecast, by Drug Type
9.5.7.4. Rest of LAMEA
9.5.7.4.1. Market size and forecast, by Class
9.5.7.4.2. Market size and forecast, by Spectrum of Activity
9.5.7.4.3. Market size and forecast, by Application
9.5.7.4.4. Market size and forecast, by Drug Origin
9.5.7.4.5. Market size and forecast, by Drug Type
CHAPTER 10: COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Top winning strategies
10.3. Product mapping of top 10 player
10.4. Competitive dashboard
10.5. Competitive heatmap
10.6. Top player positioning, 2022
CHAPTER 11: COMPANY PROFILES
11.1. Abbott Laboratories
11.1.1. Company overview
11.1.2. Key executives
11.1.3. Company snapshot
11.1.4. Operating business segments
11.1.5. Product portfolio
11.1.6. Business performance
11.2. Alkem Laboratories Ltd.
11.2.1. Company overview
11.2.2. Key executives
11.2.3. Company snapshot
11.2.4. Operating business segments
11.2.5. Product portfolio
11.2.6. Business performance
11.3. Novartis AG
11.3.1. Company overview
11.3.2. Key executives
11.3.3. Company snapshot
11.3.4. Operating business segments
11.3.5. Product portfolio
11.3.6. Business performance
11.3.7. Key strategic moves and developments
11.4. Pfizer Inc.
11.4.1. Company overview
11.4.2. Key executives
11.4.3. Company snapshot
11.4.4. Operating business segments
11.4.5. Product portfolio
11.4.6. Business performance
11.5. Lupin
11.5.1. Company overview
11.5.2. Key executives
11.5.3. Company snapshot
11.5.4. Operating business segments
11.5.5. Product portfolio
11.5.6. Business performance
11.6. Teva Pharmaceutical Industries Limited
11.6.1. Company overview
11.6.2. Key executives
11.6.3. Company snapshot
11.6.4. Operating business segments
11.6.5. Product portfolio
11.6.6. Business performance
11.6.7. Key strategic moves and developments
11.7. Cipla Ltd
11.7.1. Company overview
11.7.2. Key executives
11.7.3. Company snapshot
11.7.4. Operating business segments
11.7.5. Product portfolio
11.7.6. Business performance
11.8. Bayer AG
11.8.1. Company overview
11.8.2. Key executives
11.8.3. Company snapshot
11.8.4. Operating business segments
11.8.5. Product portfolio
11.8.6. Business performance
11.9. F. Hoffmann-La Roche Ltd.
11.9.1. Company overview
11.9.2. Key executives
11.9.3. Company snapshot
11.9.4. Operating business segments
11.9.5. Product portfolio
11.9.6. Business performance
11.9.7. Key strategic moves and developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED
11.10.1. Company overview
11.10.2. Key executives
11.10.3. Company snapshot
11.10.4. Operating business segments
11.10.5. Product portfolio
11.10.6. Business performance
TABLE 01. GLOBAL ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 02. ORAL ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL BETA LACTAM AND BETA LACTAMASE INHIBITORS ORAL ANTIBIOTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. GLOBAL PENICILLIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 05. ORAL ANTIBIOTICS MARKET FOR QUINOLONE, BY REGION, 2022-2032 ($MILLION)
TABLE 06. ORAL ANTIBIOTICS MARKET FOR MACROLIDE, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 09. ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ANTIBIOTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ANTIBIOTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 12. ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS (CARTIS), BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS (CARTIS) ORAL ANTIBIOTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 14. ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS (UTIS), BY REGION, 2022-2032 ($MILLION)
TABLE 15. ORAL ANTIBIOTICS MARKET FOR DENTAL, BY REGION, 2022-2032 ($MILLION)
TABLE 16. ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 18. ORAL ANTIBIOTICS MARKET FOR NATURAL, BY REGION, 2022-2032 ($MILLION)
TABLE 19. ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY REGION, 2022-2032 ($MILLION)
TABLE 20. ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY REGION, 2022-2032 ($MILLION)
TABLE 21. GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. ORAL ANTIBIOTICS MARKET FOR BRANDED, BY REGION, 2022-2032 ($MILLION)
TABLE 23. ORAL ANTIBIOTICS MARKET FOR GENERIC, BY REGION, 2022-2032 ($MILLION)
TABLE 24. ORAL ANTIBIOTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 29. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 30. NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. U.S. ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 32. U.S. ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 33. U.S. ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. U.S. ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 35. U.S. ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 36. CANADA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 37. CANADA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 38. CANADA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. CANADA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 40. CANADA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. MEXICO ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 42. MEXICO ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 43. MEXICO ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 45. MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 47. EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 48. EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 49. EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 50. EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 51. EUROPE ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. GERMANY ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 53. GERMANY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 54. GERMANY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 56. GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. FRANCE ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 58. FRANCE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 59. FRANCE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 61. FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 62. UK ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 63. UK ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 64. UK ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. UK ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 66. UK ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 67. ITALY ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 68. ITALY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 69. ITALY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. ITALY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 71. ITALY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 72. SPAIN ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 73. SPAIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 74. SPAIN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 76. SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 77. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 78. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 79. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 81. REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 82. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 83. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 84. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 86. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 87. ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 88. JAPAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 89. JAPAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 90. JAPAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 91. JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 92. JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 93. CHINA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 94. CHINA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 95. CHINA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. CHINA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 97. CHINA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 98. INDIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 99. INDIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 100. INDIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. INDIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 102. INDIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 103. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 104. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 105. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 106. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 107. AUSTRALIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 108. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 109. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 110. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 111. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 112. SOUTH KOREA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 113. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 114. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 115. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 116. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 117. REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 118. LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 119. LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 120. LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 121. LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 122. LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 123. LAMEA ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 124. BRAZIL ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 125. BRAZIL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 126. BRAZIL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 127. BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 128. BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 129. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 130. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 131. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 132. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 133. SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 134. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 135. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 136. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 137. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 138. SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 139. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2022-2032 ($MILLION)
TABLE 140. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2022-2032 ($MILLION)
TABLE 141. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 142. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2022-2032 ($MILLION)
TABLE 143. REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 144. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 145. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 146. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 147. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 148. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 149. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 150. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 151. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 152. NOVARTIS AG: KEY EXECUTIVES
TABLE 153. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 154. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 155. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 156. NOVARTIS AG: KEY STRATERGIES
TABLE 157. PFIZER INC.: KEY EXECUTIVES
TABLE 158. PFIZER INC.: COMPANY SNAPSHOT
TABLE 159. PFIZER INC.: PRODUCT SEGMENTS
TABLE 160. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 161. LUPIN: KEY EXECUTIVES
TABLE 162. LUPIN: COMPANY SNAPSHOT
TABLE 163. LUPIN: PRODUCT SEGMENTS
TABLE 164. LUPIN: PRODUCT PORTFOLIO
TABLE 165. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 166. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 167. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 168. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 169. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 170. CIPLA LTD: KEY EXECUTIVES
TABLE 171. CIPLA LTD: COMPANY SNAPSHOT
TABLE 172. CIPLA LTD: PRODUCT SEGMENTS
TABLE 173. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 174. BAYER AG: KEY EXECUTIVES
TABLE 175. BAYER AG: COMPANY SNAPSHOT
TABLE 176. BAYER AG: PRODUCT SEGMENTS
TABLE 177. BAYER AG: PRODUCT PORTFOLIO
TABLE 178. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 179. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 180. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 181. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 182. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 183. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 184. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 185. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 186. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
